Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doravirine + dolutegravir + lamivudine
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of three antiretroviral medications: doravirine (a non-nucleoside reverse transcriptase inhibitor, NNRTI), dolutegravir (an integrase strand transfer inhibitor, INSTI), and lamivudine (a nucleoside reverse transcriptase inhibitor, NRTI). Based on the provided information, this specific three-drug combination does not appear to be available as a single approved fixed-dose combination product, though its individual components and other combinations involving these drugs (like doravirine/lamivudine/tenofovir, dolutegravir/lamivudine, or doravirine/dolutegravir dual therapy) are used for HIV treatment.
02
Targets
Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on doravirine + dolutegravir + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doravirine + dolutegravir + lamivudine.